Skip to main content

Recent News

labs2.jpg

Novel Proteomic Biomarker Set in Osteoarthritis

Feb 02, 2023

NIH funded researchers from Duke University have developed a set of serum proteomic biomarkers that successfully predict clinically relevant knee osteoarthritis (KOA) progression (both structural change and joint pain) over a 2 year period.

Read Article
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Among our 24 speakers, Dr. Sergio and Monica Schwartzman will cover All in the Family Rheumatology. Dr. Philip Conaghan will cover Insights into the Future of OA and more.https://t.co/plpNqGu1HI https://t.co/mgMox5SpGN
Feb 02, 2023
PNAS has a novel approach to #RA Tx; bioengineered probiotic(Lactobacillus reuteri) orally delivers a peptide Kv1.3 channel blocker to RxRA. Kv1.3 is expressed on CCR7− effector memory T cells. Blocking Kv1.3 improves RA & PSO in rat models. https://t.co/DyyXi2GUH2 https://t.co/8nDyFv9DWx
Feb 02, 2023
Deptof Veterans Affairs has awarded $1.2 million to Matlock Jeffries, MD of the Oklahoma Medical Research Foundation to study the connection between obesity, gut microbiome and cartilage changes leading to osteoarthritis of the knee. CONGRATS @matlockj https://t.co/M3807QD5K2 https://t.co/ypJNunbWWS
Feb 02, 2023
Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi or other MOA biologic. ~40% had prior bDMARDs. Retention was higher w/ 2nd JAK (918d)i vs other options. TNFi (335d) or OMA (918d). https://t.co/3A3KwVcTCN https://t.co/UFLPGfmzNv
Feb 02, 2023
Herpes Zoster with JAK Inhibitors A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids.https://t.co/BO7CgcuRKR https://t.co/gyMivn5YxL
Feb 02, 2023
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/bAqa5wKIYE https://t.co/LnlcQtQnm8
Feb 02, 2023
The EMAs CHMP has recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. https://t.co/WztKcNDFl1 https://t.co/Cq3Cyr3YqX
Feb 02, 2023
Rretroperitoneal fibrosis Tx is fraut-steroids, tamoxifen, MMF, B cell therapy? OL trial in 8 RPF pts used steroids & mTOR inhibitor sirolimus (2mg/d x 3d; 1mg/d); 12 & 48wks - decr in fibrous tissue 50%, ESR 70%, IgG4 50% w/ normalized renal funct. https://t.co/9BJchCctDi
RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts - study shows that NFATC1 associated superenhancer RNA, which is formed during osteoblast differentiation, can be used as a treatment target to reduce erosions https://t.co/gCITdJKPRP https://t.co/HENbYJcOId
Feb 02, 2023
ACR20 Jefferson Memorial

ACR Urges CMS to Reconsider Copay Assistant Programs in CMS Proposed Rule

Feb 01, 2023

The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.

Read Article
hidradenitis.jpg

Hope for Biologic Treatment of Hidradenitis Suppurativa

Feb 01, 2023

A meta-analysis of trials using biologics [adalimumab (ADA), ustekinumab (UST) and secukinumab (SEC)] in the the management of hidradenitis suppurativa (HS) suggests promising results, but more controlled, rigorous studies are needed.

While only adalimumab is currently FDA approved for this inflammatory skin disorder, numerous trials with other biologics exist or are in progress.

Read Article
Studies in 76 systemic sclerosis (SSc) pts (& animal models of SSc) show fibroblast A20 (enzyme) is downregulated and promotes fibrosis in SSc; but is repressed by DREAM, an A20 negative transcriptional regulator. https://t.co/30PuO4XRuq https://t.co/VJuAJHGbut
Feb 01, 2023
Join us at RheumNow Live this March! Dr. Janet Pope ( @janetbirdnope) will be back to discuss decisive therapeutics in RA.https://t.co/0IkJsGpH6s https://t.co/TwM6AAW97X
Feb 01, 2023
US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). Downward trend in DM/PM mortality (<7%); plus PM/DM was 2X more likely to be one of mult causes, instead of, sole cause of death. https://t.co/9KZKr8JxUE https://t.co/7acK0eHVku
Feb 01, 2023
Systematic review of MRI confirm degenerative meniscus tears compared arthroscopic meniscectomy (APM) vs non-surgical or sham Rx. Results: 10 trials, 605 patients showed at 24 mos F/U, no advantage in Function or QOL favoring APM - rec conservative Rx https://t.co/4CwicQ9Jac https://t.co/3IrSRkNgqp
Feb 01, 2023
How do you treat latent TB? This and more on last week's RheumNow podcast.https://t.co/4gUXFUDTFM https://t.co/TgT6ZyewZJ
Feb 01, 2023
Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans? Apparently so, according to a new study. A combination of proteins and antioxidants doubles the anti-inflammatory properties. https://t.co/As8lhxnifp https://t.co/eZKD8Y6oTx
Feb 01, 2023
shingles_0.jpg

Herpes Zoster with JAK Inhibitors

Jan 31, 2023

JAK inhibitors are approved for several immune-mediated inflammatory diseases and carry a higher than usual risk of herpes zoster in certain conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.

Read Article
Amgen launched its adalimumab biosimilar - Amjevita ( FDA approved in 2016), has 2 different discounts— 55% or 5% below Humira's (list $6,922/mo). Another report says Amjevita 40mg given q 2wk will cost $40,497 - $85,494 annually https://t.co/iGtJUa991N https://t.co/PTPTUskUaa
Jan 31, 2023
×